NAVB - Navidea Biopharmaceuticals Stock Price, News & Analysis

$0.41 0.00 (0.00 %)
(As of 11/24/2017 01:31 PM ET)
Previous Close$0.41
Today's Range$0.41 - $0.42
52-Week Range$0.29 - $1.16
Volume406,800 shs
Average Volume539,568 shs
Market Capitalization$67.52 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.65

About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

Navidea Biopharmaceuticals logoNavidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. NAV5001 is an iodine-123 (I-123) radiolabeled single-photon emission computed tomography (SPECT) imaging agent being developed as an aid in the diagnosis of Parkinson's disease (PD) and other movement disorders, with potential use as a diagnostic aid in dementia. NAV4694 is a fluorine-18 (F-18) radiolabeled positron emission tomography (PET) imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease (AD) and mild cognitive impairment (MCI).


Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryHealth Care Equipment
SectorHealthcare
SymbolNYSEAMERICAN:NAVB
  • Previous Symbol: NYSEMKT:NAVB
  • CUSIP63937X10

    Debt

    Debt-to-Equity RatioN/A
    Current RatioN/A
    Quick RatioN/A

    Price-To-Earnings

    Trailing P/E RatioN/A
    Forward P/E RatioN/A
    P/E GrowthN/A

    Sales & Book Value

    Annual SalesN/A
    Price / SalesN/A
    Cash FlowN/A
    Price / CashN/A
    Book ValueN/A
    Price / BookN/A

    Dividend

    Annual DividendN/A
    Dividend YieldN/A

    Profitability

    Trailing EPS($0.07)
    Net IncomeN/A
    Net Margins-515.33%
    Return on Equity-65.90%
    Return on Assets-42.98%

    Miscellaneous

    EmployeesN/A
    Outstanding Shares162,260,000

    Frequently Asked Questions for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

    What is Navidea Biopharmaceuticals' stock symbol?

    Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."

    How were Navidea Biopharmaceuticals' earnings last quarter?

    Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) posted its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.01) EPS for the quarter. The biopharmaceutical company earned $0.22 million during the quarter. Navidea Biopharmaceuticals had a negative return on equity of 65.90% and a negative net margin of 515.33%. View Navidea Biopharmaceuticals' Earnings History.

    Are investors shorting Navidea Biopharmaceuticals?

    Navidea Biopharmaceuticals saw a decrease in short interest in October. As of October 31st, there was short interest totalling 4,493,794 shares, a decrease of 2.8% from the October 13th total of 4,621,391 shares. Based on an average daily volume of 901,427 shares, the days-to-cover ratio is presently 5.0 days. Approximately 2.9% of the shares of the company are sold short.

    Who are some of Navidea Biopharmaceuticals' key competitors?

    Who are Navidea Biopharmaceuticals' key executives?

    Navidea Biopharmaceuticals' management team includes the folowing people:

    • Eric K. Rowinsky M.D., Chairman of the Board (Age 60)
    • Michael M. Goldberg M.D., President, Chief Executive Officer, Director (Age 57)
    • Jed A Latkin, Chief Financial Officer, Interim Chief Operating Officer, Chief Accounting Officer (Age 41)
    • Frederick O. Cope Ph.D., Senior Vice President - Pharmaceutical Research and Clinical Development, Chief Scientific Officer (Age 69)
    • William J. Regan, Senior Vice President - Global Regulatory Affairs and Quality Chief Compliance Officer (Age 63)
    • Mark I. Greene M.D. Ph.D., Director (Age 67)
    • Michael Rice, Director (Age 51)

    Who owns Navidea Biopharmaceuticals stock?

    Navidea Biopharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Sowell Financial Services LLC (0.42%). Company insiders that own Navidea Biopharmaceuticals stock include Brent L Larson, Jed Latkin and William J Regan. View Institutional Ownership Trends for Navidea Biopharmaceuticals.

    Who sold Navidea Biopharmaceuticals stock? Who is selling Navidea Biopharmaceuticals stock?

    Navidea Biopharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Sowell Financial Services LLC. View Insider Buying and Selling for Navidea Biopharmaceuticals.

    How do I buy Navidea Biopharmaceuticals stock?

    Shares of Navidea Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

    What is Navidea Biopharmaceuticals' stock price today?

    One share of Navidea Biopharmaceuticals stock can currently be purchased for approximately $0.41.

    How big of a company is Navidea Biopharmaceuticals?

    Navidea Biopharmaceuticals has a market capitalization of $67.52 million.

    How can I contact Navidea Biopharmaceuticals?

    Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.


    MarketBeat Community Rating for Navidea Biopharmaceuticals (NAVB)

    Community Ranking:  2.8 out of 5 (star star)
    Outperform Votes:  92 (Vote Outperform)
    Underperform Votes:  75 (Vote Underperform)
    Total Votes:  167
    MarketBeat's community ratings are surveys of what our community members think about Navidea Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

    Analyst Ratings

    Analysts' Consensus Rating for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

      (How are Consensus Ratings Calculated?)
    Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
    Consensus Rating:N/A (Score: NaN)
    Analysts' Consensus Price Target: N/A

    Consensus Price Target History for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

    Price Target History for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

    Analysts' Ratings History for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

    Show:
    No equities research coverage for this company has been tracked by MarketBeat.com

    Earnings

    Earnings History and Estimates Chart for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

    Earnings by Quarter for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

    Earnings History by Quarter for Navidea Biopharmaceuticals (NYSEAMERICAN NAVB)

    DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
    11/7/2017Q3 2017($0.01)$0.22 millionViewN/AView Earnings Details
    8/8/2017Q2 2017($0.02)$0.61 millionViewListenView Earnings Details
    3/29/2017Q4 2016($0.02)$3.36 millionViewN/AView Earnings Details
    8/4/2016Q216($0.03)($0.04)$5.24 million$5.40 millionViewN/AView Earnings Details
    5/17/2016Q1($0.03)($0.02)$4.63 million$4.70 millionViewListenView Earnings Details
    3/23/2016Q415($0.04)($0.02)$3.70 million$4.00 millionViewListenView Earnings Details
    11/4/2015Q315($0.04)($0.05)$2.40 million$3.98 millionViewListenView Earnings Details
    7/30/2015Q215($0.04)($0.06)$2.18 million$2.90 millionViewListenView Earnings Details
    5/12/2015Q115($0.03)($0.05)$3.30 million$2.10 millionViewListenView Earnings Details
    3/5/2015($0.04)($0.05)$1.95 million$2.20 millionViewN/AView Earnings Details
    3/5/2015($0.04)($0.05)$1.95 million$2.20 millionViewN/AView Earnings Details
    3/5/2015Q414($0.05)($0.05)$2.10 million$2.20 millionViewListenView Earnings Details
    11/6/2014Q314($0.06)($0.05)$1.54 million$2.30 millionViewListenView Earnings Details
    8/6/2014Q214($0.07)($0.07)$1.05 million$1.05 millionViewListenView Earnings Details
    5/7/2014Q114($0.10)($0.06)$0.90 million$0.75 millionViewListenView Earnings Details
    3/6/2014Q413($0.08)($0.10)$0.74 million$0.54 millionViewListenView Earnings Details
    11/6/2013Q313($0.08)$0.09$0.97 million$0.40 millionViewListenView Earnings Details
    8/7/2013Q2 2013($0.07)($0.09)$0.55 million$0.20 millionViewN/AView Earnings Details
    5/8/2013Q1 2013($0.07)($0.06)$0.02 millionViewN/AView Earnings Details
    3/6/2013Q4 2012($0.08)($0.08)ViewN/AView Earnings Details
    11/8/2012Q312$0.21($0.09)ViewN/AView Earnings Details
    (Data available from 1/1/2011 forward)

    Estimates

    Earnings Estimates for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

    No earnings estimates for this company have been tracked by MarketBeat.com

    Dividends

    Dividend History for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)
    No dividend announcements for this company have been tracked by MarketBeat.com

    Insider Trades

    Insider Trading and Institutional Ownership History for Navidea Biopharmaceuticals (NYSEAMERICAN NAVB)

    Insider Trades by Quarter for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)
    Insider Trades by Quarter for Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)

    Insider Trades by Quarter for Navidea Biopharmaceuticals (NYSEAMERICAN NAVB)

    Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
    6/29/2017William J ReganSVPBuy20,000$0.53$10,600.00View SEC Filing  
    5/30/2017Jed LatkinCFOBuy7,600$0.44$3,344.00View SEC Filing  
    5/22/2017Jed LatkinCFOBuy25,359$0.45$11,411.55View SEC Filing  
    12/1/2015Brent L LarsonCFOSell12,500$1.50$18,750.00View SEC Filing  
    10/1/2015Brent L LarsonCFOSell12,500$2.27$28,375.00View SEC Filing  
    9/1/2015Brent L LarsonCFOSell12,500$1.88$23,500.00View SEC Filing  
    6/1/2015Brent L LarsonCFOSell12,500$1.24$15,500.00View SEC Filing  
    5/29/2015Gordon A TroupDirectorBuy10,000$1.31$13,100.00View SEC Filing  
    11/14/2014Michael M GoldbergDirectorBuy100,000$1.08$108,000.00View SEC Filing  
    11/10/2014Brendan A FordDirectorBuy10,000$1.03$10,300.00View SEC Filing  
    5/9/2014Mark Jerome PykettCEOBuy10,000$1.34$13,400.00View SEC Filing  
    3/10/2014Brent LarsonCFOSell41,500$1.96$81,340.00View SEC Filing  
    3/10/2014Frederick CopeSVPSell15,000$1.96$29,400.00View SEC Filing  
    3/10/2014Mark Jerome PykettCEOSell120,000$1.96$235,200.00View SEC Filing  
    11/8/2013Brendan FordDirectorBuy20,000$1.45$29,000.00View SEC Filing  
    11/8/2013Brent LarsonCFOBuy5,000$1.39$6,950.00View SEC Filing  
    11/8/2013Frederick CopeSVPBuy3,500$1.43$5,005.00View SEC Filing  
    11/8/2013Mark Jerome PykettCEOBuy10,900$1.35$14,715.00View SEC Filing  
    3/15/2013Gordon A TroupDirectorBuy7,000$2.70$18,900.00View SEC Filing  
    3/15/2013Mark Jerome PykettCEOBuy1,850$2.70$4,995.00View SEC Filing  
    3/15/2013Thomas H TulipEVPBuy17,500$2.82$49,350.00View SEC Filing  
    3/15/2013William J ReganSVPBuy5,000$2.71$13,550.00View SEC Filing  
    9/14/2012Thomas H TulipEVPBuy15,000$2.70$40,500.00View SEC Filing  
    9/12/2012Brendan A FordDirectorBuy5,000$2.64$13,200.00View SEC Filing  
    9/11/2012Mark Jerome PykettCEOBuy4,000$2.64$10,560.00View SEC Filing  
    (Data available from 1/1/2013 forward)

    Headlines

    Latest Headlines for Navidea Biopharmaceuticals (NYSEAMERICAN NAVB)

    Source:

    Social Media

    Social activity is not available for this stock.

    Financials

    Chart

    Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Chart for Friday, November, 24, 2017
    Loading chart…

    This page was last updated on 11/24/2017 by MarketBeat.com Staff

    Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.